CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Dermatomyositis; Polymyositis Interventions: Drug: anti-CD19 CAR T cell therapy Sponsors: University of Erlangen-N ürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)
Conditions: Lupus Nephritis; Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV Interventions: Biological: KYV-101 anti-CD19 CAR-T cell therapy; Drug: Standard lymphodepletion regimen Sponsors: Kyverna Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Biological: LMY-920 Sponsors: Luminary Therapeutics; Nationwide Children Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus Interventions: Biological: RJMty19 (CD19-CAR-DNT cells) Sponsors: Guangdong Ruishun Biotech Co., Ltd; RenJi Hospital; Peking University People ' s Hospital; Changhai Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Rheumatology Diet Study
Conditions: Diet Habit; Rheumatologic Disease; Autoimmune Diseases; Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Dermatomyositis/Polymyositis; Sjogren ' s Syndrome; Systemic Lupus Erythematous; Scleroderma; Fibromyalgia Sponsors: University of Central Florida Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Conditions: Systemic Lupus Erythematosus, SLE Interventions: Drug: PIT565 Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus Interventions: Biological: Obecabtagene autoleucel (obe-cel) Sponsors: Autolus Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Belimumab in SLE Synovial Inflammation and Lymph Nodes
Conditions: Systemic Lupus Erythematosus Interventions: Drug: Belimumab Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); GlaxoSmithKline Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Conditions: Lupus Erythematosus, Systemic Interventions: Biological: single dose of CNCT19 Sponsors: Juventas Cell Therapy Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Conditions: Systemic Lupus Erythematosus (SLE) Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Idiopathic Inflammatory Myopathies; Systemic Sclerosis Interventions: Biological: CD19-CAR-DNT cells Sponsors: RenJi Hospital; Guangdong Ruishun Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients
Conditions: SLE, and Organ Damage Index Sponsors: Sohag University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Conditions: Safety; Effective Interventions: Drug: RD06-04 Cells injection Sponsors: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Fatigue in Lupus Intervention Programmes (FLIP)
Conditions: Systemic Lupus Erythematosus Interventions: Behavioral: Standard Care; Behavioral: 4 week FMP; Behavioral: 7 week FMP Sponsors: University of Edinburgh; Accord Clinical Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Drug: FT819; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Bendamustine Sponsors: Fate Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
